<SEC-DOCUMENT>0001628280-25-051035.txt : 20251110
<SEC-HEADER>0001628280-25-051035.hdr.sgml : 20251110
<ACCEPTANCE-DATETIME>20251110161006
ACCESSION NUMBER:		0001628280-25-051035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251110
DATE AS OF CHANGE:		20251110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Skye Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42009
		FILM NUMBER:		251466266

	BUSINESS ADDRESS:	
		STREET 1:		11250 EL CAMINO REAL, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 410-0266

	MAIL ADDRESS:	
		STREET 1:		11250 EL CAMINO REAL, SUITE 100
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Emerald Bioscience, Inc.
		DATE OF NAME CHANGE:	20190325

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nemus Bioscience, Inc.
		DATE OF NAME CHANGE:	20141030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>skye-20251110.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:92d82c83-318f-4d12-9933-22a34db85677,g:3188e241-ab76-41b8-85f6-510660ff65af,d:48f99c2aefaa4f0abe8b0c17cb85a3c3-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>skye-20251110</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-19">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-20">0001516551</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="skye-20251110.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001516551</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-10</xbrli:startDate><xbrli:endDate>2025-11-10</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i48f99c2aefaa4f0abe8b0c17cb85a3c3_1"></div><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">the Securities Exchange Act of 1934</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">November 10, 2025</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.993%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SKYE BIOSCIENCE, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.993%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.018%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.018%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Nevada</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">000-55136</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">45-0692882</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">11250 El Camino Real</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite 100</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">92130</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(Address of principal executive offices)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">858</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">410-0266</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">_________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report)</span></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.</span></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:5.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:91.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:100pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.826%"><tr><td style="width:1.0%"/><td style="width:31.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.769%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Title of each class</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Symbol(s)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Name of each exchange</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">on which registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Common Stock, par value $0.001</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">SKYE</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Nasdaq Global Market</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i48f99c2aefaa4f0abe8b0c17cb85a3c3_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On November&#160;10, 2025, Skye Bioscience, Inc. (the &#8220;Company&#8221; or &#8220;Skye&#8221;) issued a press release providing a corporate update and reporting its financial results for the period ended September&#160;30, 2025.  The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.</span></div><div style="text-align:justify;text-indent:27.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:27.75pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release filed as Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.573%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.883%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="skye-20250930xfinancialres.htm">Press Release, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="skye-20250930xfinancialres.htm">November</a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="skye-20250930xfinancialres.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="skye-20250930xfinancialres.htm">10</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="skye-20250930xfinancialres.htm">, 2</a></span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="skye-20250930xfinancialres.htm">025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.090%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i48f99c2aefaa4f0abe8b0c17cb85a3c3_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.859%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;SKYE BIOSCIENCE, INC.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November 10, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/s/&#160; Punit Dhillon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Name: Punit Dhillon</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Title: Chief Executive Officer</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>skye-20250930xfinancialres.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i47118f785b6a40ba80609f2a6e0d2ec6_1"></div><div style="min-height:72pt;width:100%"><div><img alt="skye-biosciencexdarkblue.jpg" src="skye-biosciencexdarkblue.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:371px"></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Skye Bioscience Reports Third Quarter 2025 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:14pt;font-weight:700;line-height:120%">Financial Results and Business Update</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:9.65pt">Topline nimacimab Phase 2a study data showed clinically meaningful weight loss in nimacimab&#47;semaglutide combination cohort versus semaglutide alone after 26 weeks of treatment&#59; the data demonstrated a clean neuropsychiatric safety profile and no increase in gastrointestinal adverse events.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#171a40;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:9.65pt">Nimacimab plus semaglutide showed additional reduction in waist circumference of -3.2 cm vs. semaglutide alone.</font></div><div style="margin-top:6pt;padding-left:27pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:9.65pt">Rebound weight gain was lower in the 12-week post-treatment follow-up period in patients treated with nimacimab plus semaglutide vs. semaglutide alone.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:115%">SAN DIEGO, CA, November&#160;10, 2025 -- Skye Bioscience, Inc. (Nasdaq&#58; SKYE) (&#8220;Skye&#8221; or the &#8220;Company&#8221;), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the third quarter ended September&#160;30, 2025, along with key accomplishments and upcoming milestones.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">&#8220;As we obtain additional data from our CBeyond Phase 2a study, a holistic review provides us with additional confidence that nimacimab&#8217;s biology is active and has the potential to fill notable gaps in the obesity and overweight landscape in order to support a healthier weight loss journey for patients,&#8221; said Punit Dhillon, President &#38; CEO of Skye. &#8220;With the positive combination data, we are shifting our focus to a combination development pathway while simultaneously planning to further understand nimacimab&#8217;s potential benefit in a monotherapy setting. We anticipate that forthcoming biomarker data and the readout from the 26-week extension will continue to build upon this story and provide further insights into nimacimab&#8217;s full potential as a metabolic therapy.&#8221; </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%">Clinical Highlights&#58; CBeyond</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:7.15pt;font-style:italic;font-weight:700;line-height:115%;position:relative;top:-3.85pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%"> Phase 2a Obesity Trial</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Phase 2a Data Highlights&#58; </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">In October 2025, Skye reported 26-week topline data from its ongoing CBeyond Phase 2a study demonstrating a 29% relative increase in weight loss when nimacimab was dosed in combination with semaglutide compared to semaglutide alone.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">At ObesityWeek 2025, Skye shared new weight rebound data highlighting that after treatment discontinuation nimacimab plus semaglutide blunted rebound weight gain compared to semaglutide alone  (18.1% versus 49.8% weight regained over 12 weeks). Moreover, at 12 weeks post-treatment, the nimacimab plus semaglutide group maintained significant weight loss compared to the placebo group.</font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">The nimacimab plus semaglutide combination also achieved an additional decrease in waist circumference of 3.2 cm (1.25 inches) compared to patients treated with semaglutide alone. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">In the context of the obesity treatment landscape, we believe that this data highlights nimacimab&#8217;s potential as a combination or maintenance therapy by supplementing GLP-1 therapeutics to enhance weight loss and improve body composition by targeting fat loss, without adding gastrointestinal side effects. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:12pt;text-align:center"><font><br></font></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%;padding-left:14.15pt">Extension Study Fully Enrolled&#58; </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">In September, Skye completed the enrollment of its 26-week extension study. A total of 43 patients were enrolled, with 19 and 24 patients in the combination and monotherapy cohorts, respectively. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">Data from the 26-week extension is expected in Q1 2026 and will provide information on the potential full treatment duration of 52 weeks followed by a 12-week follow-up period. </font></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#9702;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.11pt">In the combination arms, patients will continue with blinded treatment with nimacimab or placebo and will continue receiving semaglutide (Wegovy&#174;). Patients in the monotherapy arm will receive a higher dose of nimacimab (300 mg), which we expect will assist in refining our PK model. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Third Quarter 2025 Financial Results&#58;</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet and Cash Flow Highlights&#58;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">Cash, cash equivalents and short-term investments totaled $35.3 million as of September&#160;30, 2025. The Company expects its current capital to fund projected operations and key clinical milestones into 2027, including completion of its Phase 2a extension study of nimacimab and certain manufacturing and clinical activities, initial manufacturing runs needed to start a subsequent trial, and planning activities. In addition, our runway supports our discovery, research and development efforts along with formulation and development work in preparation for nimacimab&#8217;s later stage studies.</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operatin</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">g Results&#58;</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">R&#38;D Expenses&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">Research and development (R&#38;D) expenses for the three months ended September&#160;30, 2025, were $9.4 million, as compared to $4.9 million for the same period in 2024. The increase was primarily due to contract manufacturing, clinical trial costs associated with our clinical study for nimacimab, discovery research and development expenses, salaries and stock based compensation expense, and consulting advisory and professional fees. </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">G&#38;A Expenses&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">General and administrative (G&#38;A) expenses for the three months ended September&#160;30, 2025, were $3.9 million, as compared to $4.6 million for the same period in 2024. The decrease was primarily related to decreases in consulting, advisory and professional fees, recruitment fees, salaries, and stock based compensation expense.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:112%;padding-left:14.15pt">Net Loss&#58; </font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">Net loss for the three months ended September&#160;30, 2025, totaled $12.8 million, with non-cash stock-based compensation expense of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">$1.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%"> million, compared to $3.9 million for the same period in 2024, with non-cash stock-based compensation expense of </font><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%">$1.9</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:112%"> million.</font></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call Details </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Skye will host a conference call to discuss its Q3 2025 results at 1&#58;30 p.m. PT&#47;4&#58;30 p.m. ET today, November&#160;10, 2025. The live streaming of the call can be accessed at the Skye investor relations website, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:12pt;text-align:center"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">along with the Company's earnings press release, financial tables, and investor presentation. Following the call, a replay and transcript will be available at the same website.</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:107%">ABOUT SKYE BIOSCIENCE</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">Skye is focused on unlocking new therapeutic pathways for metabolic health through the development of next-generation molecules that modulate G-protein coupled receptors. Skye's strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye is conducting a Phase 2a clinical trial (ClinicalTrials.gov&#58; NCT06577090) in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy&#174;). For more information, please visit&#58; www.skyebioscience.com. Connect with us on X and LinkedIn. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:700;line-height:120%">FORWARD LOOKING STATEMENTS</font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">This press release includes &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements relating to&#58; nimacimab&#8217;s potential to fill notable gaps in the obesity and overweight landscape&#59; nimacimab&#8217;s potential as a combination or maintenance therapy by supplement GLP-1 therapies&#59; future clinical development of nimacimab, including the initiation and design of any future clinical trials&#59; the expected timing for reporting data from the Phase 2a extension study&#59; the Company&#8217;s cash runway. When used herein, words including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;planning,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. All forward-looking statements are based upon the Company&#8217;s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important risks and uncertainties, including, without limitation, the initiation and design of any future clinical trials will be impacted by the Company&#8217;s capital resources, the Company&#8217;s ability to obtain additional sources of capital, program considerations and potentially other factors outside the Company&#8217;s control&#59; the potential for additional weight loss after 26 weeks may not ultimately be observed&#59; there is no guarantee that higher dosing of nimacimab will achieve increased efficacy, and likewise it is possible that higher dosing will produce adversely different safety and tolerability results than those observed to date&#59; the Company&#8217;s dependence on third parties in connection with product manufacturing&#59; research and preclinical and clinical testing&#59; the Company&#8217;s ability to advance, obtain regulatory approval of and ultimately commercialize nimacimab&#59; competitive products or approaches limiting the commercial value of nimacimab&#59; the timing and results of preclinical and clinical trials&#59; the Company&#8217;s ability to fund development activities and achieve development goals&#59; the impact of any global pandemics, inflation, supply chain issues, government shutdowns, high interest rates, adverse regulatory changes&#59; the Company&#8217;s ability to protect its intellectual property&#59; risks associated with the Company&#8217;s common stock and the other important factors discussed under the caption &#8220;Risk Factors&#8221; in the Company&#8217;s filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2024, which are accessible on the SEC&#8217;s website at www.sec.gov and the Investors section of the Company&#8217;s website. Any such forward-looking statements represent management&#8217;s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:12pt;text-align:center"><font><br></font></div></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:11pt;font-weight:400;line-height:120%">disclaims any obligation to do so, even if subsequent events cause the Company&#8217;s views to change. These forward-looking statements should not be relied upon as representing the Company&#8217;s views as of any date subsequent to the date of this press release.</font></div><div id="i47118f785b6a40ba80609f2a6e0d2ec6_4"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div id="i47118f785b6a40ba80609f2a6e0d2ec6_7"></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.242%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.242%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.517%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended<br>September 30,</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</font></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,357,444&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,883,337&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,892,454&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,908,538&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,907,090&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,638,927&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,375,567&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,171,547&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in estimate for legal contingency</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,553,468)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,553,468)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,264,534&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,968,796&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,268,021&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,526,617&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,264,534)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,968,796)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,268,021)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,526,617)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (income) expense</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,766)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796,222&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(418,474)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(907,697)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,609,807)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,296,488)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gains from asset sales</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,400)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,837)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(180,763)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,217,978)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (income) expense, net</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(509,874)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,070,499)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,790,570)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,716,044)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,754,660)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,898,297)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,477,451)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,810,573)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,400&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,071&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss </font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,754,660)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,898,297)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,482,851)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,820,644)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per common share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.32)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.05)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.48)</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares of common stock outstanding used to compute loss per share&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,665,927&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,819,387&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,654,512&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,317,352&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,665,927&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,819,387&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,654,512&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,317,352&#160;</font></td><td style="background-color:#ffffff;border-top:0.5pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i47118f785b6a40ba80609f2a6e0d2ec6_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SKYE BIOSCIENCE, INC. AND SUBSIDIARIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br>2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br>2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,441,079&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,415,741&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,871,229&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,712,311&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,962&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900,175&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,209,544&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,924,794&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,827,247&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033,965&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,432,752&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311,620&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449,864&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,910&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,910&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,324,289&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,763,773&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,825,005&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,252&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920,774&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114,255&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366,123&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,201&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimate for accrued legal contingencies and related expenses</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054,357&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,818,751&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, current portion</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,638&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,428&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367,897&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,338,887&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-current liabilities</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,207&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273,162&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,488,104&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,612,049&#160;</font></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $0.001 par value&#59; 200,000 shares authorized at September&#160;30, 2025 and December&#160;31, 2024&#59; no shares issued and outstanding at September&#160;30, 2025 and December&#160;31, 2024</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value&#59; 100,000,000 shares authorized at September&#160;30, 2025 and December&#160;31, 2024&#59; 30,989,046  and 30,974,559 shares issued and outstanding at September&#160;30, 2025 and December&#160;31, 2024, respectively</font></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,989&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,975&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,237,719&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,070,421&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</font></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172,432,523)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(130,949,672)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,836,185&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,151,724&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,324,289</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,763,773</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTACTS</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Investor Relations</font></div><div style="margin-top:6pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">ir&#64;skyebioscience.com</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(858) 410-0266</font></div><div style="margin-top:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Advisors, Mike Moyer</font></div><div style="margin-top:6pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">mmoyer&#64;lifesciadvisors.com</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(617) 308-4306</font></div><div style="margin-top:6pt"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Media Inquiries</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LifeSci Communications, Michael Fitzhugh</font></div><div style="margin-top:6pt"><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">mfitzhugh&#64;lifescicomms.com</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(628) 234-3889</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>skye-20251110.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:92d82c83-318f-4d12-9933-22a34db85677,g:3188e241-ab76-41b8-85f6-510660ff65af-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:skye="http://skyebioscience.com/20251110" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://skyebioscience.com/20251110">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20251110_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20251110_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="skye-20251110_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://skyebioscience.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>skye-20251110_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:92d82c83-318f-4d12-9933-22a34db85677,g:3188e241-ab76-41b8-85f6-510660ff65af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://skyebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="skye-20251110.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://skyebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f0f44e7b-461c-4428-bf24-fc110c980171" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_53a43101-eb3e-4226-907d-fc91af261d98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_f0f44e7b-461c-4428-bf24-fc110c980171" xlink:to="loc_dei_DocumentInformationTable_53a43101-eb3e-4226-907d-fc91af261d98" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>skye-20251110_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:92d82c83-318f-4d12-9933-22a34db85677,g:3188e241-ab76-41b8-85f6-510660ff65af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c0273713-8213-4179-a953-113d402a7b05_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_33817bd0-41ff-40f9-b826-29f8fe928c40_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_52fc2c8e-22ce-4a39-8305-16efb673f8b1_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_b1b5ef19-d65a-487e-bbd4-5b11961827ec_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_d684ed31-f8a7-49a0-a692-8eae7fbd4b0c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_60015d02-2c62-467c-b664-df3f0e398d9a_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_fc63ce4e-1fc4-4e4f-b68f-0f54472722ed_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_7ece5ed7-bc16-4a09-8678-c1384c60bf43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_46141a5e-5bb9-42b7-afc6-a8045a3e751c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_e4763d2e-800d-451d-aa0b-c915593c65ac_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b2d5aa47-ea91-4161-ac7a-9401ef8d7b62_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3ee38598-09b4-4246-b1c3-d0a5a7623166_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_9b3ecba0-ec23-4663-a1bb-bce74d65fbb5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2ba29cca-1d79-45c1-95e5-5f744063ffea_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_39fee58b-fbc5-4683-9dda-cb0aa6902842_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_59f163ef-685e-44d9-9e29-25d88f902d13_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d07deb9c-e615-4aa4-8660-6be031a7804f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_216869f1-1adb-4a4d-bdc0-711a764cc574_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_e56afcbb-9c0e-4bd7-aec2-df0ba126b921_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_49be3b44-dbd9-4af0-b1f6-8985e5413b81_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6acf2a03-5519-427d-b199-36c48cf820f6_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_50d2d81e-495c-49c8-be53-62336d6fffbf_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>skye-20251110_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:92d82c83-318f-4d12-9933-22a34db85677,g:3188e241-ab76-41b8-85f6-510660ff65af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://skyebioscience.com/role/CoverPage" xlink:type="simple" xlink:href="skye-20251110.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://skyebioscience.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2a03bfc8-7fa4-4796-9fa4-5dfff31cb644" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_DocumentType_2a03bfc8-7fa4-4796-9fa4-5dfff31cb644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_65d9e8f8-0570-42aa-95e4-91b19c0e91a1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_DocumentPeriodEndDate_65d9e8f8-0570-42aa-95e4-91b19c0e91a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cd1049c0-36e3-4451-aa8e-4c112b392c2c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityRegistrantName_cd1049c0-36e3-4451-aa8e-4c112b392c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9279702f-4306-47ad-944e-bdfff0ff2b17" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9279702f-4306-47ad-944e-bdfff0ff2b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_23941c61-3c38-41cb-817d-f079d44a0762" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityFileNumber_23941c61-3c38-41cb-817d-f079d44a0762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b05fdf70-379c-432a-af60-228d5d9d70ef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityTaxIdentificationNumber_b05fdf70-379c-432a-af60-228d5d9d70ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e1d23cf6-1170-4a81-8630-1a0b2ed34223" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityAddressAddressLine1_e1d23cf6-1170-4a81-8630-1a0b2ed34223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_95e8f7b8-d09b-4a62-a47f-ef686f559e14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityAddressAddressLine2_95e8f7b8-d09b-4a62-a47f-ef686f559e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_4ea7762b-86ca-4360-a5c2-e3ee5ff05c07" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityAddressCityOrTown_4ea7762b-86ca-4360-a5c2-e3ee5ff05c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0585dbaf-f8a0-48ea-980f-241daeb8c090" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityAddressStateOrProvince_0585dbaf-f8a0-48ea-980f-241daeb8c090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7436a18a-7130-4e53-b1d2-b121ebf1a172" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityAddressPostalZipCode_7436a18a-7130-4e53-b1d2-b121ebf1a172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_80a8a01e-b1aa-4972-ac0c-b685e5b46266" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_CityAreaCode_80a8a01e-b1aa-4972-ac0c-b685e5b46266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_760521f9-2db7-4f2b-a15d-13dc69bb4f00" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_LocalPhoneNumber_760521f9-2db7-4f2b-a15d-13dc69bb4f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_05f53ea3-5f2f-4b6b-9a30-a3462866fed6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_WrittenCommunications_05f53ea3-5f2f-4b6b-9a30-a3462866fed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_a3913fc0-423f-42a9-b969-222bd002a4bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_SolicitingMaterial_a3913fc0-423f-42a9-b969-222bd002a4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_6b9be533-cd03-47c5-996f-a3f7a44d9ad8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_PreCommencementTenderOffer_6b9be533-cd03-47c5-996f-a3f7a44d9ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_16d77ae0-5f15-4c2f-9623-f51c6d910d77" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_16d77ae0-5f15-4c2f-9623-f51c6d910d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b30f58da-fc50-4bf2-80b7-a0616ac2c0d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityEmergingGrowthCompany_b30f58da-fc50-4bf2-80b7-a0616ac2c0d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e47c7c6b-61a8-4875-8d49-1087f7626e15" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_AmendmentFlag_e47c7c6b-61a8-4875-8d49-1087f7626e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e25b9001-5ecd-4759-ad59-2e4ce3cd688f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_EntityCentralIndexKey_e25b9001-5ecd-4759-ad59-2e4ce3cd688f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_53a43101-eb3e-4226-907d-fc91af261d98" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_cec2adaa-b370-4819-ba9a-ae2dce6a6f98" xlink:to="loc_dei_DocumentInformationTable_53a43101-eb3e-4226-907d-fc91af261d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_f0f44e7b-461c-4428-bf24-fc110c980171" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_53a43101-eb3e-4226-907d-fc91af261d98" xlink:to="loc_dei_DocumentInformationLineItems_f0f44e7b-461c-4428-bf24-fc110c980171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>skye-biosciencexdarkblue.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 skye-biosciencexdarkblue.jpg
MB5!.1PT*&@H    -24A$4@  #08   * " 8   !T+D2C    "7!(67,  "XC
M   N(P%XI3]V   @ $E$051XG.S=T7';6+8NX'6FYEV^;ZC"@W0BD&X$)B*P
M3@3F1&"="*R)P)H(S(Z@U1& CJ#E"$9^8!7?KAS!W =L6K1:DD6*Y,8&OJ^*
MI;;;3:ZV!&)S8_U8__6?__PG                @++\+7<!
M    P.8$@P               *! @D$               !0(,$@
M        *)!@$                !1(, @                *)!@$
M            !1(, @              @ ()!@$              $"!!(,
M              "@0()!                4"#!(                "B0
M8!                 42# (                "B08!
M  42# (              ( ""08!              ! @02#
M    H$""00               % @P2                 HD& 0
M        %$@P"                 HD& 0                %$@P"
M          "  @D& 0              0($$@P               *! @D$
M              !0(,$@                *)!@$                !1(
M, @                *)!@$                !1(, @
M@ ()!@$              $"!!(,               "@0()!
M    4"#!(                "B08!                 42# (
M        "B08!                 42# (              ( ""08!
M          ! @02#                H$""00               % @P2
M               HD& 0                %$@P"                 HD
M& 0                %$@P"              "  @D& 0
M0($$@P               *! @D$               !0(,$@
M    *)!@$                !1(, @                *)!@$
M        !1(, @              @ ()!@$              $"!!(,
M          "@0()!                4"#!(                "B08!
M               42# (                "B08!                 42
M# (              ( ""08!              ! @02#
MH$""00               % @P2                 HD& 0
M    %$@P"                 HD& 0                %$@P"
M      "  @D& 0              0($$@P               *! @D$
M          !0(,$@                *)!@$                !1(, @
M               *)!@$                !1(, @              @ ()
M!@$              $"!!(,               "@0()!
M4"#!(                "B08!                 42# (
M    "B08!                 42# (              ( ""08!
M      ! @02#                H$""00               % @P2
M           HD& 0                %$@P"                 HD& 0
M               %$@P"              "  @D& 0              0($$
M@P               *! @D$               !0(,$@
M*)!@$                !1(, @                *)!@$
M    !1(, @              @ ()!@$              $"!!(,
M      "@0()!                4"#!(                "B08!
M           42# (                "B08!                 42# (
M             ( ""08!              ! @?Z>NP     8JZINSB+BS2_^
MV,,_,__5\RX7[2__#           4+[_^L]__I.[!@   "A>53<G$7&2?CE)
M7]]$%^Q9>7NP@G[V-2+NTC_?ID=$Q$WZ_=OEHKW]RW\%          #TFF 0
M    O%!5-Y.X#_N<K#V.<]6T8]_C/BQT$_<AHIOEHKU[^C\#          !R
M$ P"  " !ZJZ.8O[\,\DAA7^V=8J-+1ZW"X7[3QK10          ,'*"00
M (S:6@AHDKZ>9BVH/%_C/BPT7R[:F\SU          # : @& 0  ,"I5W4RB
M"P%-(N)MSEH&[$M$S*,+"LWSE@(          ,,E& 0  ,"@I8E YR$(E-,J
M*'1MHA           .R.8!    "#4M7-F^B"0*LPT%'6@GCH>T1<QWU0Z"YO
M.0          4"[!(    (I7U<U)=$&@:42<YJR%C?T175!(2 @
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MY]$%@OS<\"O'$?$I(BZKNKF*;HJ0@!  VSJ*%#Y=_<9:6&@>$?/EHIUGJ0P
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M7+2WN8O8IZINS@6".)"CB/@874#H(G<Q  S>NXCX7-7-754W5Z8( 0
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M=YG+*-&WY:*]R5W$2Z7I*3?A>\UX'$7$YZIN9KD+ 6!43B/BUN0Z
MX*4$@P  8#/3W 7TT#1W 86:Y2[@I=+4E'ET4U1@;-Y7=6-Z P"'=!3=Y"#A
M(        ."7!(,  & SIQKT_F*:NX!"S7(7\!)5W5Q%Q.?H&E1AK-Z&!FT
M#DLX"        '@1P2   -C<-'<!?5'5S7F8(K.-K\M%>YN[B.=4=?.FJIMY
M1'S(70OTQ&EHT ;@L(2#        @%\2# ( @,V=YRZ@1_Q=;&>6NX#G5'5S
M$A'SZ*:D /=6#=K>^P XE*.(N*[JYDWN0@       (!^$@P" (#-'6L*[R;*
M1,3[W'44:I:[@*>D.]+?1#<=!?BKHXCXO:J;:>Y" !B-X^B"J<)!
MP%\(!@$ P'9&'PR*B&GN @KUQW+1WN4NXC$I%#2/+O@ /.^S<!  !W0:$5>Y
MBP        #Z1S (  "V\]X=N^,B=P&%NLY=P&-2P.'/$ J"30@' 7!([ZNZ
ML08'        ?B(8!   VQOMU*"J;B81<9R[C@)]CQX&@U*PX7/N.J!0PD$
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MSD,H"/;I*"+F5=V<9*X#@&2Y:.?+17NY7+1G$?'?$?&/B/B:N:Q=>)L"WP
M     ,"("08! ,#KC6F"SC1W 87ZUH?I(2G$-LM=!XS 4723@][D+@2 GRT7
M[>URT<[60D+_BHCOF<MZC4OG&P       !@WP2   'B]\]P%'$)J.'R?NXY"
MS7(7D$)!\^@""\#^G4;$=>XB 'A:"@E=1,1)1/PSR@P('<>X;E0
M//#WW 4  ,  '%5U<[Y<M$-O )_F+J!@LYPOGD)=UR$4!(?VMJJ;J]1T#D!/
M+1?M7723=ZZB"]E\S%S2IB[2^>8N=R$O<!M="*L$M[D+  " +=R&-3<   ",
MCF 0  #LQC2&/QE"8_MVOBX7[6VN%T^AH'ET=Y,'#N]#53<WRT4[RUT( ,];
M"PC-H@MVO\U:T,L=1?=YY"IS';^4UL67F<L  (#!LN8&  " <?I;[@(  & @
MWJ4 QB!5=3,)P9)MS3*__E5$G&:N <;NJJJ;L]Q% / RRT5[NURTDRCG+ML1
M0OP        P6H)!  "P.^>Y"]BC:>X""I9MDE15-Y<1\3[7ZP,_'$7$]9 #
MI !#M%RTEQ'11,3WS*6\Q'%5-T/^/ (        \03 (  !V9Y!WZ4Z-[)H,
MM_/'<M'>YGCAU!CZ,<=K X\ZCOP3Q #8T'+1SB-B$F6$@P;Y>00       !X
MGF 0  #LSFE5-R>YB]B#\^BF7;"Y+-."TL_A+,=K \]Z5]6-IFV PBP7[4V4
M$0YZ.]#/(P       , S!(,  &"WAMCP/<3_IT/)$@Q*KRO,!?UT6=7-6>XB
M -A,0>&@:>X"        @,,2# ( @-TZSUW +J7F]=/<=13JM^6BO3OTBU9U
M<Q6^9]!G1V&B%T"14CAHFKN.7YCF+@         X+,$@  #8K>.J;B:YB]@A
MTX*V=_!I057=G$?$AT._+K"QTZIN+G,7 <#FEHOV.B+^F;N.9QR;3 <
M  #C(A@$  "[-\U=P"Y4=?,F!C8!Z8"^IZ;1@ZGJYB1,(8&2?-2X#5"FY:*]
MC(BON>MXAC4\        C,C?<Q<    #-)1&O/.(.,I=1*$./BTHNE"0[U=9
MOJ2OM^FQ,M_BN=Y$Q'K(9)*^GH6?BSZ;Q<_?-P#*,8V(/W,7\83SB+C,700
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M^/8.,2WH)"+>[_MU1N9KF!*T4^GO\BQZV!A=H,O<!0"PL7GN AYQEKL
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MA>69!@Z>DNY^/(UQ-/GNRJIIX]K> MMPW+W(ZH[_CC/()%V'6 6&K;=_)FQ
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MC8BW*71V:4TQ7&EZYVHZD#VFW7IXLPSG/U;[NM/T<#[:C?7C[#),$6)+@D$
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MM]%-K]'PF]?;B&BKNIFG9DT&9G7,575S&UUSCF;<PSN*[OWNWU7=S-(>*O!
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MOR<UGT=:E_B>._4_O]54QIGI.;)2?Q_.U?_N1A]G?DK?P8T["%[N!W<
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M>93OX8WSHJQ6N9_"EKZ+E^X<"7.Z0:0Z/$GZ9([RKBBK>=?6C3D''D%C$
M  [E7%+M#C%"9Y)6:3)@-#L-&0TYD7DZX+7&Y+UB%:L!X3$9!P#[$[@IZ'>>
M]7C, 78Q?BT6D ,*V!QTI+[H(<>FQPCS,TMW@(DZ4W_";81QPI'&47RXE'3L
M#G$/A;MF@9N#CBF\GZY4B![E>?4+OX=Q=&U]6935+_(W*N3<>!].^L[>USW/
MV&*/NK:^2"=.1IH'D6)L(/%J >>8))J"[+::@]:*-3[?S"TMO#%>[4)Q_E[/
MF=.-(S4'S>6?S[T0]4]A_> .    @'%*16I7[APC]&ZK*2C*9$#.+@>\UFS
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M)^E_Z@<<G]0/_-^IGY2?0F'FV_3G8_I32_JS**O_*\IJG?Z.ED59+5*W/P
M!Y$6PWYWYP"2NZ$7^-/B 0 ,)=).RP 03E%69T59->KGRB(4[W[/G:0Y!8;X
MGF"G!;%[><92H>#"G2,Y3@4ET;G'WFP$%TN4 KJY.\"N NV*+$FWBO,,Q ZZ
MMK[0MXTR(^#$Q!$+=%K0@N:._*2BY"_&"$?B'?<2KVU&H*'!XT+]?%H4<W>
MYPCTOI,XD3H[Z7T7J2YHX0ZPBT#?Q0MW #Q?^BZ^,48X+LJ*9W4@G!B$+*4F
MEOM_IM#HLT_'Z<]?@_ETTM"-^H6D:TG7&75- P#B6ZK_D.2=#3='D=K,<$T
M   DJ7'B7'%.PMC%IBF(HF\\9>D.D+![^0BD4T]^E_3!G47!=YP,L@D([XA
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MYNX 3TGONRBG!?W.W.@H+-T!DG=13]3=P_MF'VYI9AV' *<&G46]UZ;F1W<
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MI'/FS_!,48HVHN3 GJ4BCBOY=R]]7Y05STCDI)&_"'%FOOZCTJ[(4<;9"W<
M[-52,=8=%F)\-";NG^6=)!H81Z1KZ[6Y4/I,_M_KZ!8O_,_1T!!(U];7:7/K
M"/6),W> '2S< 1*:8<?E7#0&/2C(J92WZ<1PC$2:R[V5;\.,A8+=:U/T@SL
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MJY]0BS!XQKB\DU079=44935WAP$0RPB;@J3^7;ITAS!R+ZY@_+X$F> !  #
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MN+28?2WI@SL+L ='DGXKRJH)]#$%X)EH"OK+L:2I-CM>*$91!?)VFXZB!@
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M,W<'4-[W$(;1N ,H1H'31H[S5N\EU459K8NRNDBG]0&O-7,'4(SG$X#X9NX
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MV+9V!\ P.#$H3RMW &!BWA5E==ZU]84["!!5:DBA:=7OHBBKRXF=<K907UB
M:?HRL=]W -@9ST< >+YTBL%I45;GZD\0.K(&>ARG7$_#S!T@X7<,N[B1=&+.
M$*+0:5O7ULNBK,[D_[N)YDA]T]#?3FA()PW=J2^^7&OKQ"%.&LK.S!U %+P
MV$&0#1<600I' 2GN/(@3C0P8@PCO.P##6Z1Y*0 30F-09M)I#"P@ ,-;%F75
ML'L!\$^I*>B3.P<D]9.U%^J;92:A:^NF**LKW2LDP&1<N@,\ V,( $.Z<@<
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M;./T5M([;34-I8:A=6H:6A9E=<8<!   0,R3.$W6[@# GD288V*='%,S=P<
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M6X[2J?0 ,"4S=X!]Z-KZ0IP>-'9'DCZJ;Q!B?0D  " 8-C\ ]HM["E.2:N\
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M43JE'@"F8#(%?*E!Z%32?]2O\41J2L5^O)6TYCT.   &QAH6?P<8E[4[
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M(9*W[@  @)C2_,M:]^8JTKSRJ:19^G.J_G0HWBE^F^:@>=?6T0HK&DD?W2$
M(!-775O/W2$ _,/:'0  @%?ZM6OKI3L$@.'1&!3'J3M 1JZZMF[<(2;B7/WO
MYHD[2(;F[@" ]-?B;2/IV!P%+T=3T,BD$[QXMSYMY0YP2%U;?RW*ZD;\+KS$
M0FP4    \M H3F.04O%PX\Z!G5V)XGO@N=;N &.2&DZ:A_ZUHJQF^GNST#S]
M(_,<PSE1/W_&Z<H/8&,9  #P4B/?N!#3$VTC 0  <$ T!L7! M_NENX 4Y$*
M5A>2_G1GR= QBPYPVVH*8C$V7S]W;;URA\#>+=P!,C&%D_<:\8Q^B;D[
MP(X:=X![YHJ7";'-W & YZ" ;SB/G3(D_:UI:*Z^66ASZA";5^W?NZ*L+KJV
M9@.5?WKC#@    "X=6U]7925.P8P1>Y-8F?&:P,PHC$H@+1K/'9SPZZ6PTH?
M"+]*^NC.DJ&Y)!J#8$%3T"C0%#1>[.+YM"\3*>9I%&@'^8R<%&4UF\CO"
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MQL,B[#K*?!S"28V4"W>.;459S0V7C7!_CKW(#,_C_GU@'!Y4U]:-.X/\OY\
M@/%KW &4-I]QAT , 1KWKP:X!M_%  9%8Q!R<\;@$, 8T124-9J"\#=%69V*
MXO9=T!CT?2MW@)'XS53X@F=()V2Y=R@;@R_LX@\ P&@U[@!B 1GWI/D/MSOF
MY!!5.BE[B"*C73GNV<9PS?N.BK*:N4,@C+GY^KRS8KLQ7W]NOCX 8.2"-,)*
MO//PS=P=X-""S%O-W0$ #(?&(.3F2.S #V!D: K*&DU!>,C"'2 #=ZDX H](
MNX)_=N<8B<L@!6MX0%%6"TD?W3E&@N<J ,0U<P= ]B+,.\S= 1#.W!U ,>X-
MX'N6[@!;!I\;"31O/G<'0!CN.4(V=(G-_<R*<!(C &#\W(VP$N-S?.,>GS<#
M7<>]:8C[[QG @'YT!X#6X@/_N<Z+LKI@)V0 8Y"*86D*RA--07C,F3M !BA>
MW\V%>$?LPY%2<Q#?$+&DAJT+=XX1X=D* '%QHBA>JY&_F9IU#-PW=P?0@*>1
MI)-.'=9=6Z],U\8K=6W=%&5UI1C/T)GINA'^]\_%Z=SHN0OB6$^*[5KF^?BB
MK.:!3G,  (Q3(^G$G&%NOC[BF)NO/U3MP+6\W\4G15F]H58"F 8:@_S6[@ 9
M.E(_>4O1+8"LI::@3^X<>!&:@O"@5.1.T=_3*%[?0=?6UX&*1W)W+*E)"ZM,
M> 60GI>-^N\[O-X7?K<!(*:BK-ZX,R!_J;#<'8-"1=PW=P?0@(U!\C7G78F&
MAMQ=*,;<CJLAHI'_?__<?'T$4)353/ZY^[7Y^OB^QAU _?.J,6<  (Q;(^F#
M.0--"MAP?RL.5?/5R'_?S46=#C )/[@# "_T+A74 T"6: K*VJUH"L+C%NX
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M9>U&_4E!'&>,!Q5E=2:*-7:Q<@?(T(4[P,ALFH/XCAA8&@?]*9Z5^Q:A2!@
M\#C&'-B7QAU T@F%BDCF[@"*<4\,@N_746C< <P:=P#%>&[!RUU\2EU('AIW
M /&\ @ <7N,.(-YW\/\.##T^;P:^WGW'S"\!T_"C.P!$<?'K'*DOZIMS>@.
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M- 7A)5B<>=H7[JO]2)-%G]TY)F!S"BD-0D\HRFI6E-5*TI_J-V? ,"YXK@)
M;.D$PH@G//#^R%^$QB IQB(^!I2*!B*<F.RZ!]:FZV[,S=?'*Z4YG:F+\ ZC
M"&I"4F.%?0,;"J"R%.%YM7 '@,W<=6'&*\#D1'C?';$6.QWI6RS">K+S=S_"
M?<>&&1.4UJQ<<[LWINM.$HU!,33N !-QI'[W[S]3@=\%.ZP!V+>TR$!34)YH
M"L*SF3^<<K)R!QB9<_6GA>#PCD6#T(.*LIJGAJ#_2GIOCC,UG!8$ 'D(N8$
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M]D<H:-2$@MB51>X"1N"BA*:=.>B[]J*JFP^1_^1"'N]%?'[/_]N4T8B_'!@
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M-DT6NJKJYKRJFX4%=4;F*(2"QDHHB'U9Y"Y@!&PB9):: A>9RP">YW0$B]0
MLY<VR4I__UWE+H"#6>8N8,O2)O)HK:*< U&6N0OXBG7N I*SM-E/X=(],?<^
MPV7F[_^@PL*M+T+CRJBD?>=5WBK^0O/3A*7 <BGWTI5W@'%+ >_<[]V7Z3D,
M<-\R=P%;+CSSQB/]K$I['U[F+N!;"@OD><\<OU7D7X,:0R!OL@2#RK3*70#L
MV.N(>!L1OT?$_Z:I0JL4%/(B0<E^COPO2CR=4!#[Y!2VK[.)4(@T<OI=[CJ
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MX,\IKO-S'<.4KE7N0J8L-:3]$-:DIF9S"K)3R)F$K7N5?;WINHMA2M"Q"9W
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ML'=9IX(=2E4WZQA/<SM"05"DK0!1Q.?/,?<=I:_O=16? S[;-M-]_OR[!D,
M .8@O8=OWK^/MKYRAH9,XF0R'MB[V_S]9937R+$Y%.,F?;G^*%8Z1?DHRGU^
M;?YT_<",I7O59M+"=@]/[G> S?2?B+_>LZR+ _!="GWF;3[C;O:'U^%9QT1\
MX3-Q[FLNXN_OF=:6*(Y@$).Q]0(F.$2)_B='@[9@$!S$9=^U)[F+V*=T0L-5
MC/.DW;D1"@(  (!'NA?@/[GW?SZ*IP7WU_?^?I.^(FP.,V-;X:&-DP?^8]O3
M=Q_K_B$8&^NM?^W:8Y(\OX QV.KAB7CX67_RQ/_*]3?^/2>R Y#%GM_/MS_[
M"OY ?/,]\TN'M'[-^M[?_[+F9"HN8R(8Q&P(#I'9O_NNO3CT-Q4,@H-YUW?M
M,G<1^Y2>H^OPS"S9A[YK%[F+              Y', @2P2'V+$NSMF 0'%0S
M]1,"JKI91,3ON>O@09,/IP$           !_)Q@$CR0XQ#/=]EU[=.AO*A@T
M:[<1\2IW$3-S%Q%'4Q]17]7-*B)^SET'?[J+B$6.J70           ! ?H)!
ML"."0SS"O_JNO3GD-Q0,FJWKB#B)B+.(^#5O*;-SW7?M<>XB]JVJFZN(>)V[
M#N(ZAE#05>Y"            @#P$@^! !(>(B#=]UZX.^0T%@V;I0]^UB\U?
MJKI91\2/V:J9I_=]UY[E+F*?JKIY&1$WX?F5T_N(6$Y]0A4           #P
M=8)!4 C!H5GX2V#C$ 2#9N=OOV-5W1Q%Q%6XCQS:O_NNO<A=Q#ZEY]9_<M<Q
M0W<Q3 F:].\7            \#B"03 2#P2'3B+B*")>Y:N*)[KMN_;HD-]0
M,&A6OA@\J^KF-"+^.&PYLW<7$<=]U][D+F2?JKHYBXC?<M<Q(Q]C" 69$@0
M          !$A& 03$)5-R<Q!(8V7Z^S%L37_,\A&[H%@V;CE[YKS[_V'ZCJ
MYCPBWAZH'@;7?=<>YRYBWZJZ647$S[GKF+C;B#@S)0@           "X3S (
M)JBJF\U$H9.(. U3A4K2]%V[/M0W$PR:A3=]UZZ^]1]*]X5U" X>VON^:\]R
M%[%/?K?V[EU$G)L2!            #Q$, AFH*J;HQ@"0HO0N)W;N[YKEX?Z
M9H)!D_>H4-!&53?',00X7NRK(![TI)_3&*7GS%7XW=JE#Q&Q[+OV)G<A
M        0+D$@V!F4O/V(GV9)'1X'_JN71SJFPD&3=9=1"SZKKUXZO]C53=G
M$?';[DOB*^XBXJ3OVJO<A>Q353<G$='FKF,"+F,(!*US%P(           "4
M3S (9JRJF].(.(N('W/7,B.7?=>>'.J;"09-TK-#)E7=7$3$3[LKB4>XCN'G
M]BEW(?M4U<TR(G[-7<=(?8R(<X$@            X"G^D;L ()^^:R]22*6)
M84(!^R>$Q7/L:O+,(B)NGU\.3_ Z(LYS%[%O?=<N8PBX\'@?(N)??=>>"@4!
M            3V5B$/"GJFY.(F(5$:_R5C)Y_W.HJ2$F!DW*=40L=A *BH@_
MK_=V%_]=/,F;OFM7N8O8IZIN7D;$.H8P% ^[C2$HMIKZ%"D           !@
MOTP, OZ4)A4<1\3[S*5,W7'N AB=Z]C-I* _I>O]W:[^^WBT\ZIN)GT/2$&7
M10P3KOCL+H;I0#_T77O4=^VY4!            #P7"8& 0]*TT0N(N)%YE*F
MZ-]]UUX<XAN9&#0)FU#07@($5=VL(^+'??QW\T5[_9F6HJJ;TXCX(W<=F=W%
M\"R].-1]'P           )@7$X. !Z5I(D<Q-+"S6Y.>%L).7<;^ R2+,-GE
MT%Y'Q"IW$?N6@C!SG$!W'<,TKA_ZKGW9=^U"* @           #8%Q.#@*^J
MZN9E1*QC:&1G-][U7;L\Q#<R,6C4/O1=NSC$-S+9)9M?^JX]SUW$OLU@*M5E
M1%S%\*Q<3WT2%            % 6P2#@FX2#=NZR[]J30WPCP:#1.E@H:*.J
MF_.(>'O([TE$#%-EKG(7L4_I&7(5$:]RU_),=S'\[_CS:^H_.P
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MN8O@T181T>8N B;@+B)."PR#+"+B*@0 #^VBJINCOFL_Y2X$
M@''X1^X"(#G.70"/ET(,U[GK@)&[BXB3 D-!D8(IB]QUS-"+B+C(700
M        XR$81"E>Y"Z )SO/70",V"84=)6[D"])@:5WN>N8H1^KNEGF+@(
M          " <1 ,.HQ/N0L8@ZIN3 T:EXL8P@U\AZIN7N:N@6RNH_!0T$;?
MM<N(N,Q=QPS]6M7-2>XB             "B?8-!A%-_\78BCW 7P>'W7?HHA
M',3W$82;I]&$@K8L0@@PAPL!0@            "^13"(D@A*C,\Z=P$P(IM0
MT*BFR/5=>Q-#.(C#>A'NL0            !\@V 0)3G)70!/MLY= (S$98PP
M%+31=^U%1+S/7<<,O:[JYCQW$0            "42S#H,-:Y"Q@)$X-&)DT2
MN<U=!Q3N0]^UHPT%;5G&,/6(PWI;U<UI[B(             *)-@$"5Y4=6-
M<-#XW.0N  KVH>_:1>XB=B$%FQ81<9>YE#E:575SE+L(             ,HC
M&'085[D+&)&3W 7P9.O<!4"A)A,*VNB[]BJ&R4$<UHN(N,A=!
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M!AV6*2&/]\(D!*!@US%,"KK)74@)^JZ]B(CWN>N8H1<1L:KJYF7N0@
M      #(0S#HL&8]5>([+',7P*-H2'\Z]X)QVX2"3'[ZJV4(P.;P.B)6N8L
M            ( _!H,,2!GB:5U7=G.4N@F\ZSEW " F4C-?'$ IZ4/IGLHB(
MN\RES-%/GI<             \R08=%CKW 6,T+*J&Q-IRN;G\W0WN0O@NWSH
MN_94*.C+^JZ]"M/><OFMJAM!30           ("9$0PZH-0P;9+"T[P(3>:E
MTXC^=#>Y"^#)/O1=N\A=Q!CT77L>PV0E#N]"F!8           !@7@2##F^=
MNX 1>EO5S4GN(O@BP:"GN\E= $_R7BCHR181<9N[B!EZ%1&KW$4
M    <#B"08>WSEW 2)V;@E">JFZ.8YCJQ!/T77N3NP8>[7W?M6>YBQB;OFL_
MQ1 .XO!^JNK&[RP           # 3 @&'=XZ=P$C]3HBEKF+X&].<A<P0M>Y
M"^!)/N4N8*SZKEU'Q+O<=<S4;R;M 0           ,R#8-"!]5U[%1&WN>L8
MJ;=5W9SF+H*_6.0N8(1N<A< A])W[3(B+G/7,5,7)NT!            3)]@
M4!X7N0L8L555-\>YBR"BJINC&"8Y\317N0N  UM$Q%WN(F;H17C?
M     )@\P: \UKD+&+$780I"*1:Y"QBI=>X"X)#ZKKT)]XM<?JSJ9IF["
M          #V1S H@[YK+\+TA.=X%1%KX:!\TC_[L]QUC)2)0<Q.>NZ]SUW'
M3/U:U<U)[B(             V _!H'PN<A<P<J]#."BGLQBF-_$TMWW7?LI=
M!&2RC(CKW$7,E$E[             !,E&)2/8-#S"0=E4-7-49@6]+W6N0N
M7%(H;A$FYN7P(MQ_             "9),"B3OFLO(N(V=QT3(!QT>*LP+>A[
M7>4N '+JN_8JALE!'-[KJF[.<Q<!            P&X)!N5E:M!NO(Z(JZIN
MCG,7,G55W9Q%Q(^YZQBQ=>X"(+>^:\\CXF/N.F;J;54WI[F+
M &!W!(/R<G+_[KR*87*0AN<]J>KF)")^RUW'B-VF:2E Q"),S<ME5=7-4>XB
M             -@-P:",^JZ]B8C+W'5,R(N(^*.J&X&K'4O3F$RX>IYU[@*@
M%'W7?HHA',3AO0CW<P           (#)$ S*3XAE]]Y6=7.5PBP\4_KGN(ZA
MF9SOIQ$?MO1=NXZ(=[GKF*G70K0             TR 8E%G?M1<1<9N[C@EZ
M'1'_J>IFF;N0,:OJYC2$@G9EG;L *$W?M<LP.2^7MU7=+'(7 0
M ,#S" :5P:G]^_-K53<W*>#"$Z10U1\A%+0+'_NN_92[""C4(B+N<A<Q4^>F
MZP$           ",FV!0&5:A*7J?7D7$'U7=K*NZ.<E=3.FJNCFJZN8J(G[-
M7<N$7.0N $K5=^U-#.$@#N]%1*RJNGF9NQ              OH]@4 '2)!%3
M@_;OQXAH!80>5M7-RS0EZ'\CXG7F<J9&, B^HN_:BXAXG[N.F7H=WD$
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M)4X42A.!-D&@S9\F4.7S/[D#928&/9N)01FD>]E5>!;F\DO?M>>YBP
M      #@VP2#"I0F);2YZ^!1KB/B)H8&]IOT]6F?H:&M\$_$$/S9_/TH--'Q
MA-T\   /\DE$0527Y$/?M8O<10@&/9M@4":>A=G]4&( %@           ("_
M$@PJ5%4W%Q'Q4^XZ>+;KB-B>&'.3OK[E.(; S\;+B'B]LZHXA'_U77N3NPC!
MH&<3#,JHJIME1/R:NXZ9NHV(X]Q3SP            #XNG_F+H O.HMA&LR+
MS'7P//?#/#]FJ8)#^U!"* C&KN_:99H<Y-YY>*\B8A41IYGK
M . K_I&[ !Z60@7+S&4 WV>9NP"8D$5$W.4N8J9^JNKF+'<1
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M=0            ! 3H)!X[6(B.O<1<",W<9P'0*9]%V[C(C+W'4
M    0"Z"02/5=^VGB#@)X2#(Y31=AT!>IQ%QE[L(             ,A!,&C$
M4BAA$1JBX=#>]%U[E;L(X"_/0@            "8'<&@D4OAA),0#H)#^=!W
M[2IW$<!G?==>1,3[W'4             P*$)!DV <! <S,>^:Q>YBP#^KN_:
MLXBXSET'             !R28-!$" ?!WEU'Q")W$<!7+<)S$
M ( 9$0R:$.$@V)OKB#CIN_93[D* +TO/P;/<=0            # H0@&34QJ
MBCZ*(<@ /)]0$(Q(W[6KB/B8NPX             . 3!H E* 8:3$ Z"YQ(*
M@G%:1,1M[B(             8-\$@R:J[]I/?=<>1\2'W+7 2 D%P4BEZ_8T
M=QT             L&^"01/7=^TB(G[)70>,C% 0C%S?M5<1\2YW'0
M      "P3X)!,]!W[7E$_#LB[G+7 B-P&4)!, E]URYCN*8!
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MP&'U77L5$6>YZP            " 71$,(B+^,CVHB8C;W/7 GKSKN_8XA0.
M&>J[=A6"L             !,A& 0?]%W[;KOVJ.(>!<1=YG+@5VY#%."@,\6
M(00+            P 0(!O&@%* XBH@/>2N!9[F+B#=]UYZ8$@1L]%W[*2).
M<]<!             ,\E&,07]5W[J>_:143\*X:)*S F[R+BJ._:5>Y"@/*D
ML."[W'4             P',(!O%-?=?>]%U[$A%-" A1O@\1\:^^:Y=I*@C
M@])T/,\U             $9+,(A'Z[MV+2!$P3:!H$7?M3>YBP%&XS0B[G(7
M 0            #?0S"()]L*"/T00Q@#<A(( KY;FBRVR%T'
M 'P/P2"^6]^U5WW7+B+B7Q'Q/DQ<X'#N0B (V)&^:R]B>(X!
MP*@(!O%L?=?>]%U[%A%'$?$F(J[S5L2$W4;$+Q%Q)! $[%)ZCGE^ 0
M     # J_\Q= -/1=^VGB%A%Q*JJF^.(.(N(TXAXD;,N)N%C1*S25 ^ ?5E$
MQ#H\MP             8"1.#V(N^:Z_ZKEW$YRE"'[,6Q!AMI@/]J^_:4Z$@
M8-_ZKKV*(=0*            _/_V[N"FC3"*PNA+&L#+D681=X [B*>#E)!2
M4A(=V'1@.C +2U[2 5G,C&(194&$_?N:<Z31@)"LNT%L^/2 ""X&<59OK@@M
M:[P@]+.J[IN-XIH]5]5#C=>!=JW' )_/\;"9K]ZM/N@C%^5O'@
M  !G\N7U];7U!CZADTCH1U5];SJ&UL1 9]3UPZ_6&\)MCX?-MO4(F'7]L*B/
MBY:JQG#IO9_G]P(           #@2@B#:&[Z)^<?5;6>WG=-!W$)CS7&0 _'
MPV;?> L              $02!G%UNGY8U9]0R#6AV_!45=OY.1XV+TW7
M          # #1 &<?6Z?EC7& FM2RB40@@$              !G)@PBSG11
M:%U5J^FY;SJ(YZK:3<^VJG9"(               .#]A$#=ANBHTAT++<EGH
M7)YJ#(#V)0("             ("FA$'<K*X?EC5&0NOIO:PQ'+IKLRC&<XWA
MS_QLJ^KE>-CLFBT"              #^(@SB4^KZ8555BQJCH:HQ&%K4& ]]
M:[/J8AZG]WYZ7FJ\ B3^ 0            " (,(@^(>N']8GWYY^/4=$LT55
MW5]@TEM/-48]LSGPF>U.?KX_'C;["^T"               N0!@$9]3UP[+&
M*T3_Y7C8;#]H"@              <&.$00               !#H:^L!
M            P/L)@P               ""0, @                ""8,
M               @D# (                 @F#                () P
M"                 ()@P               ""0, @                "
M"8,                @D# (                 @F#
M() P"                 ()@P               ""0, @
M   ""8,                @D# (                 @F#
M    () P"                 ()@P               ""0, @
M       ""8,                @D# (                 @F#
M        () P"                 ()@P               ""0, @
M           ""8,                @D# (                 @F#
M            () P"                 ()@P               ""0, @
M               ""8,                @D# (                 @F#
M                () P"                 ()@P               ""0
M, @                ""8,                @D# (
M @F#                () P"                 ()@P
M ""0, @                ""8,                @D# (
M     @F#                () P"                 ()@P
M     ""0, @                ""8,                @D# (
M         @F#                () P"                 ()@P
M         ""0, @                ""8,                @D# (
M             @F#                () P"                 ()@P
M             ""0, @                ""8,                @D# (
M                 @F#                () P"                 ()
M@P               ""0, @                ""8,                @
MD# (                 @F#                () P"
M  ()@P               ""0, @                ""8,
M   @D# (                 @F#                () P"
M      ()@P               ""0, @                ""8,
M       @D# (                 @F#                () P"
M          ()@P               ""0, @                ""8,
M           @D# (                 @F#                () P"
M              ()@P               ""0, @                ""8,
M               @D# (                 @F#                () P
M"                 ()@P               ""0, @                "
M"8,                @D# (                 @F#
M() P"                 ()@P               ""0, @
M   ""8,                @D# (                 @F#
M    () P"                 ()@P               ""0, @
M       ""8,                @D# (                 OT&# A!GQ$P
.["4     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Nov. 10, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SKYE BIOSCIENCE, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-55136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-0692882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11250 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">410-0266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>20</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="skye-20251110.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://skyebioscience.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="skye-20251110.htm">skye-20251110.htm</File>
    <File>skye-20251110.xsd</File>
    <File>skye-20251110_def.xml</File>
    <File>skye-20251110_lab.xml</File>
    <File>skye-20251110_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "skye-20251110.htm": {
   "nsprefix": "skye",
   "nsuri": "http://skyebioscience.com/20251110",
   "dts": {
    "inline": {
     "local": [
      "skye-20251110.htm"
     ]
    },
    "schema": {
     "local": [
      "skye-20251110.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "skye-20251110_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "skye-20251110_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "skye-20251110_pre.xml"
     ]
    }
   },
   "keyStandard": 20,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 20
   },
   "report": {
    "R1": {
     "role": "http://skyebioscience.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "skye-20251110.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "skye-20251110.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://skyebioscience.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-25-051035-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-051035-xbrl.zip
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M<JO^D[E5$@3<8U?PZ@)][8R^G(#3UW"[D6,F7%RSK^+!D/"(DTE'\!NN'0
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M225.O9LJ'^4O1'X#4D#X(LWN#'R3Q2D8 5B)T(#G%M<'3J]?6"3 #!8G 5(
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M4=^?.Q%JN0F&&( 2>9.Y%2(DG,GYWYHR^.!0D>DO.MI(?Z#":1"DU+-,A]?
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M<HOQWDCKD<,;#9L[S?:;O23TCO7E-A%?6;32RDC9C)EIE\^:7>MC^S<ON&T
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M853D:9R,1I\68[N: HT(8ODH01')4Y3&98)B$B1)4)9)S,J65(KZ?NP^.6O
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M:J"8^$:OX6!4M;&G^YL$Y]O>,%BXP?XVX1>NDWUNX*/WQG3P&U!+ P04
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MG\:E>73V9OM,LOZ/GF=O_@=02P,$%     @ 0H%J6UQ]S?&N!@  3#$  !4
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M%]7G>^<)(M[#*D@?6<88[<W^_.7EY1</+A*TB,W0XA.\<5=';^VYWL!U!W6
MVW9N[%2-OU>HZE5NTN;-RCJHAKM%@+(8:CYT;9>L[PH/GMM@+7$BIT1J9HBS
MQA(+/'A05D6C[S>^=[Q%SX>@M.#W5LVG)5:,P>&R_](K(P=5'IB[5>=Y?F_^
MA6=8MN"6"A>])GFTDLC<*&+Z;UF(,0KFG9)R*[>_MG;?ZZ^C>IC\HDD!$G8C
M&W,V^7L1?@CP78GEA4U8$?'G914V;\?4K*>(5==,H-QM6-#=W06V.D)*$$YN
MH_)DXX:6==BYPE!RBHB?0BJ;\*8.OV+O6Z@L&-!1$YKU*G#4PV0@B6&.&4_!
M,,LF"?T]LZ,8X/-GX/E:OC ,;^JN[&[>PZKLE:B[/^P:"A\8E>@H$0H$D3+#
MH=)J(-(SQITPW'._%0N/61V%@I@O"ELK.0L2CG'&EBZ:- C_ ?6'H^:R[M+-
M41.@,#PW.>4XMQ(49TZY#<1("<3UO1S.G+AC^01@?->)49S(N7,RG<ZSP.9M
M6<$?EVL'J>#"2.85(\(+C;-K[XAF>2"1YB9(:6FN^ 2,?+$X"HAL[D \4\%9
M1/_,7A\'U*J,Y>U"Y*XACF8Q1!1#Y,8CRQS%B(KB>DP''")#3B%.@,(3YD=Q
MH>;.Q13:S@*2PQ P!.W=!R[<@!7  A<>E]Z,]=)8S8A6@A)FJ>,0A.1<3 #(
M(Z9'P9'/'8YM-9TI&+S Z;*.N=,D4..P$8H3*_-(("JM8I898-LM1)\T/0H,
M_>.!\?]I.B<PCO#KNW367-6%!)OCX(?CH?(6.SWL[VSF.0$!D.',*/-TBOGG
M \.CH# _"!3/U'-.2 P3YG?I-#6?RMI#03.=!6<CB=KVN@ NN#6-A$L6+#CM
MJ:'3<?&-]7%Y+/J#T+&-M'-"Y+1I.UO]4UX,"ZH<V;9,6Y(S' HE9((X'"?Q
MPAFXR"S+IUB4/&9['!XSSG-.).L+P]'W>H<)[."WIA9I9KB@9JB'-#D.A9YZ
MXI3.('-2<:6VPN%K:^, F'&2\]G2O7#(^VVQZO2\J3<+ZUS1C+-H" \N)S+B
MP&=9%@@3P2OCG(QTNV'B6XOC0C_CI.96$KYP^/]*9==!?=2LUY?UW>*YQ?$L
M9@*L(%GL\VM..6(L=EY6(+I:J0AAN[_^HV;'@3#CK.7V8KXP#1^:JO1E5]:K
MWW&"DTI;%588)J+O=VA$[+=I4 NC$&W.7:"46^FV2T\]M#F.@QDG*[>4\84A
M.$W0$]R?"1AV;OM-__0NHA^%<L;A_$40'Z@@,O<9,49%1#GF5LI@;-ANQ_YI
MV^.@F'&F<B)9YP7'<=M>0OJZ+4R%/+= L;=C&9$>NSRCN" Q8UX%PR@^GA*1
M!QZ, V7&6<M))9[%:O/-&M(*>\/?4G/5G6/C+FQ]4SA!8Z:#)=%GJ(^+G&B*
M\R5+%5/6<T^#V8J4[Q@?!\GL,YC;"_O"?!PBX:&G_&UE5P5@UY=[G!\I9C6*
MD6=$!VD(HSJ/.2Z:X,NH_RPB[ID;Q\",$Y;/%V\6O<(1>IYL=8P=V_5_X*8
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M86QR97,N:'1M4$L! A0#%     @ 0H%J6SS:D=:W#P  'WH  !$
M     ( !X"$  '-K>64M,C R-3$Q,3 N:'1M4$L! A0#%     @ 0H%J6]1C
M!N)T @  "@@  !$              ( !QC$  '-K>64M,C R-3$Q,3 N>'-D
M4$L! A0#%     @ 0H%J6R@2]&N[ @  4@D  !4              ( !:30
M '-K>64M,C R-3$Q,3!?9&5F+GAM;%!+ 0(4 Q0    ( $*!:EO!;D'%ZPD
M *%5   5              "  5<W  !S:WEE+3(P,C4Q,3$P7VQA8BYX;6Q0
M2P$"% ,4    " !"@6I;7'W-\:X&  !,,0  %0              @ %U00
K<VMY92TR,#(U,3$Q,%]P<F4N>&UL4$L%!@     &  8 DP$  %9(      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>skye-20251110_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="skye-20251110.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
        </entity>
        <period>
            <startDate>2025-11-10</startDate>
            <endDate>2025-11-10</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-19">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-20">0001516551</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-11-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SKYE BIOSCIENCE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">000-55136</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">45-0692882</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">11250 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">410-0266</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-18">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
